CSE:NOVO-B 11 December 2025

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk A/S shares climbed 4.7% in early trading on Friday after the U.S. Food and Drug Administration pledged to crack down on mass-marketing of unapproved drug copies. By 0848 GMT, the stock was up 4.9% at 294.50 Danish crowns.

6 February 2026

CSE:NOVO-B·Pharmaceuticals·Stock Market

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: the EU regulator’s support for a higher-dose Wegovy, the long-telegraphed India launch of Ozempic at a sharply lower price point, and the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand beyond obesity/diabetes into MASH. Reuters+2Reuters+2

14 December 2025

CSE:NOVO-B·NASDAQ:AKRO·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close to 50% lower than where they started 2025, putting the stock on track for its worst year on record.MarketBeat+2MarketScreener+2

11 December 2025

CSE:NOVO-B·Financial Forecasts·NASDAQ:NVO

CSE:NOVO-B 11 December 2025 - 6 February 2026

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)